<DOC>
	<DOCNO>NCT01514370</DOCNO>
	<brief_summary>This prospective , monocentric , double blind , placebo control , two arm study . Curcumin derive rhizome plant Curcuma longa ( common name , turmeric ) belong Zingiberaceae family find South Asian country , especially India large producer . BCM95 ( bioCurcumin ) combination Curcumin extract oil enhance bio-absorbability human . BCM95 may enhance prolong antioxidant anti-inflammatory effect standard therapy maintain good safety profile .</brief_summary>
	<brief_title>Dietary Supplement Curcumin Subjects With Active Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta 1a</brief_title>
	<detailed_description>The subject must experience least one Gadolinium ( GD ) enhance Magnetic Resonance Imaging ( MRI ) lesion baseline visit one Multiple Sclerosis ( MS ) relapse last 6 month screen visit . Randomization , 1:1 ratio , do two arm : 40 subject Interferon ( IFN ) beta 1 44 mcg TIW + Curcumin ( BCM 95 ) 40 subject IFN beta-1a 44 mcg TIW + placebo . The study last 42 month : 18 month enrolment 24 month treatment period . The study consist 6 visit per subject : screening visit ( Visit 0 ) , baseline ( Visit 1 ) , visit 3 month baseline ( Visit 2 ) , 6 month baseline ( Visit 3 ) , 12 month baseline ( Visit 4 ) 24 month baseline ( Visit 5 ) .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Curcumin</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Subjects early diagnosis ( 3 year ) Relapsing Multiple Sclerosis accord revise McDonald Criteria ( 2010 ) Subjects currently treatment IFN beta1a 44 mcg TIW , receive treatment minimum 6 month longer 12 month enrollment . Subjects must experience least one Gdenhancing MRI lesion baseline visit one MS relapse last 6 month screen visit . Males females 18 60 year age Subjects Expanded Disability Status Scale ( EDSS ) 05.5 No use oral systemic corticosteroid corticotropin ( ACTH ) within 30 day prior Screening visit . No use Disease Modifying Drug ( DMD ) ( IFN beta1a 44 mcg ) 12 month prior Screening visit Be willing able comply protocol Signed informed consent Pregnancy breastfeed History alcohol drug abuse Serious psychiatric disorder History presence serious acute gastrointestinal disease gastric duodenal ulcer , ulcerative colitis inflammatory bowel Crohn 's disease Subjects suffer obstruction biliary tract Any major medical condition opinion Investigator could create risk subject could affect adherence trial protocol . Subjects inadequate haematological function ( define leukocyte ≤ 2,0 x 10^9 ; platelet ≤ 100 x 10^9 ; haemoglobin ≤ 12 g/dl female ≤ 13 g/dl male ) , liver function ( define AST , ALT , alkaline phosphatase &gt; 2.0 time upper limit normal ) , thyroid function ( In particular subject clinically overt hyperthyroidism clinically overt hypothyroidism case accord physician 's discretion ) . Known hypersensitivity gadolinium Any condition would prevent subject undergoing MRI scan ( impairment Kidney function , metal prosthesis etc . ) Immunosuppressive therapy 12 month screen visit Use recognize drug involve enzyme substrate , inducer inhibitor P450 system Use antiplatelet agent antihyperlipidemics Any contraindication accord IFN beta 1a 44 mcg Summary Product Characteristics ( SmPC )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Relapsing</keyword>
	<keyword>Interferon beta 1a</keyword>
	<keyword>Curcumin</keyword>
</DOC>